Genocea Biosciences (GNCA) versus TrovaGene (TROV) Head-To-Head Contrast

Genocea Biosciences (NASDAQ: GNCA) and TrovaGene (NASDAQ:TROV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation.

Analyst Recommendations

How to Become a New Pot Stock Millionaire

This is a breakdown of recent ratings and recommmendations for Genocea Biosciences and TrovaGene, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genocea Biosciences 0 1 6 0 2.86
TrovaGene 0 1 2 0 2.67

Genocea Biosciences currently has a consensus target price of $4.79, indicating a potential upside of 410.26%. TrovaGene has a consensus target price of $2.50, indicating a potential upside of 590.42%. Given TrovaGene’s higher possible upside, analysts plainly believe TrovaGene is more favorable than Genocea Biosciences.

Volatility and Risk

Genocea Biosciences has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, TrovaGene has a beta of -0.09, indicating that its stock price is 109% less volatile than the S&P 500.

Profitability

This table compares Genocea Biosciences and TrovaGene’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Genocea Biosciences N/A -454.50% -157.78%
TrovaGene -4,932.08% -315.63% -109.54%

Insider & Institutional Ownership

10.3% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 4.6% of TrovaGene shares are owned by institutional investors. 6.7% of Genocea Biosciences shares are owned by company insiders. Comparatively, 7.4% of TrovaGene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Genocea Biosciences and TrovaGene’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Genocea Biosciences $230,000.00 334.79 -$56.71 million ($1.98) -0.47
TrovaGene $500,000.00 40.04 -$24.90 million ($0.54) -0.67

TrovaGene has higher revenue and earnings than Genocea Biosciences. TrovaGene is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform AnTigen Lead Acquisition System to design immunotherapies and vaccines that act through T cell immune responses. Its lead product candidate is GEN-003, an investigational immunotherapy that is in Phase III trial for the treatment of genital herpes infections. The company is also develops GEN-009, which is in pre-clinical stage to treat neoantigen cancer; GEN-010 that is in pre-clinical stage for the treatment of patients in second generation neoantigen cancer; GEN-007, which is in research stage to Epstein-Barr virus; and GEN-006 that is in research stage for the treatment of immune-oncology-tumor-associated antigen cancer. It license agreement with University of California and Harvard University; and collaboration agreement with Novavax, Inc. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

TrovaGene Company Profile

Trovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is in Phase Ib/II clinical trial in acute myeloid leukemia (AML) and has completed a Phase I clinical trial in advanced solid tumors. The PCM-075 is also in preclinical studies with approximately 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including Zytiga (abiraterone acetate); Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) in AML, metastatic castration-resistant prostate cancer and other hematologic and solid tumor cancers. Trovagene, Inc. primarily serves pharmaceutical companies and third party laboratories. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply